


YY1 and MyoD are transcriptional activator and inhibitor, respectively, of the *DUX4* gene that causes facioscapulohumeral muscular dystrophy (FSHD).

Ansseau Eugénie¹, Charron Sébastien¹, Guiguen Allan², Van Lint Carine², Coppée Frédérique¹ and Belayew Alexandra¹

¹Lab. Molecular Biology, University of Mons-Hainaut, Mons, Belgium; ²Lab. of molecular Virology (I.B.M.M.), Université Libre de Bruxelles, Gosselies, Belgium.




FSHD

Facioscapulohumeral muscular dystrophy is a dominant hereditary disease with a prevalence of 1/17,000. It is characterized by weakness and atrophy of the muscles progressing from the face to the lower limbs.


The *DUX4* gene

The *DUX4* gene is expressed at the mRNA and protein levels in FSHD myoblasts and muscle biopsies but not in controls.



The *DUX4* promoter is more active in muscle cells compared to other cell types. An inhibitory complex containing YY1 was described in non muscle cells and shown to bind to a *cis*-element in the *DUX4* promoter that covers a *DUX4* transcription start site. In addition, an E box (MyoD binding site) maps 3' of the TACAA box and covers the second transcription initiation site that is more often used in myoblasts.


The *DUX4* promoter has been well conserved in mammalian evolution.



In conclusion, we propose that *DUX4* expression can occur in FSHD myotubes because YY1 and MyoD are degraded at this differentiation stage.

We acknowledge funding from the : ABMM (Belgium), AFM (France). EA and AG were FNRS (Belgium) postdoctoral researchers, SC held pre-doctoral fellowship from the FRIA (Belgium). We thank the platform for human cell culture from the Institute of Myology (Paris, France) for the immortalized myoblasts.


The FSHD locus in 4q35



In non-affected individuals, the locus comprises 11-100 tandem copies of a 3.3-kb element named *D4Z4* that contains the *DUX4* gene. The FSHD deletions reduce the *D4Z4* copy numbers to 1-10 and activate genes in the vicinity by chromatin loop alterations.

Transient expression of *DUX4* promoter fused to the *LUC* reporter


Lipofection of muscle or non-muscle cells and luciferase assay: test of mutated *cis*-elements



No major inhibition in HeLa and C2C12 cells. Weak activation in TE671 cells. Inhibition of the promoter activity

Binding of YY1 and MyoD on their *cis*-element

Electrophoretic Mobility Shift Assay (EMSA)



YY1 and MyoD bind to their *cis*-element

Chromatin Immuno-Precipitation (ChIP)

